Detalhe da pesquisa
1.
Toward New AQP4 Inhibitors: ORI-TRN-002.
Int J Mol Sci
; 25(2)2024 Jan 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38255997
2.
A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9.
Eur J Clin Pharmacol
; 77(10): 1473-1484, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-33969434
3.
A Phase 1 Randomized Trial of Specific Active α-Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy.
Mov Disord
; 35(11): 1957-1965, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32882100
4.
Effects of single and combined immunotherapy approach targeting amyloid ß protein and α-synuclein in a dementia with Lewy bodies-like model.
Alzheimers Dement
; 15(9): 1133-1148, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31378574
5.
The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice.
Eur Heart J
; 38(32): 2499-2507, 2017 Aug 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-28637178
6.
Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson's Disease: A Randomized, Placebo-Controlled, Phase 1 Study.
J Parkinsons Dis
; 11(3): 1079-1089, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34092654
7.
Targeting α-synuclein by PD03 AFFITOPE® and Anle138b rescues neurodegenerative pathology in a model of multiple system atrophy: clinical relevance.
Transl Neurodegener
; 9(1): 38, 2020 09 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-32972456
8.
Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial.
Lancet Neurol
; 19(7): 591-600, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32562684
9.
Peptide-based anti-PCSK9 vaccines - an approach for long-term LDLc management.
PLoS One
; 9(12): e114469, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25474576